Table 4.
Serum sclerostin levels of the total end-stage kidney disease (ESKD) cohort and according to the percentage of sclerostin-positive lacunae (i.e., below versus equal or above the median of 43%).
| ESKD Patients All | Sclerostin-Positive Lacunae < 43% | Sclerostin-Positive Lacunae ≥ 43% | p-Value | ||||
|---|---|---|---|---|---|---|---|
| Serum sclerostin levels (pg/mL) | |||||||
| Tecomedical | 1687 | (1501) | 1524 | (998) | 2122 | (1642) | 0.0067 ** |
| DiaSorin | 1155 | (848) | 1010 | (645) | 1350 | (1307) | 0.0328 * |
| BioMedica | 3109 | (2524) | 2512 | (2374) | 4075 | ±1708 | 0.0036 ** |
| R&D | 214 | (159) | 164 | (165) | 284 | ±135 | 0.0051 ** |
Note: * p ≤ 0.05, ** p ≤ 0.01.